Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 4:27 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 6,770 matching trials from the live ClinicalTrials.gov search.
Filters: Bethesda, Maryland Clear all
Completed Phase 1 Interventional

Ebola and Marburg Virus Vaccines

NCT00605514
View directory record Official record
Conditions
Ebola Vaccines, Marburg Virus Disease, Ebola Virus Disease, Marburgvirus, Ebolavirus
Interventions
VRC-EBODNA023-00-VP, VRC-MARDNA025-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 3, 2026, 4:27 PM EST
Completed Phase 2 Interventional

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

NCT00700206
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
Ezatiostat Hydrochloride
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Tucson, Arizona • Alhambra, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Nov 3, 2026, 4:27 PM EST
Recruiting No phase listed Observational

A Natural History Study of Bone and Mineral Disorders

NCT00024804
View directory record Official record
Conditions
Tumor Induced Osteomalcia, Osteomalacia, Familial Tumoral Calcinosis
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
1 Day to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Nov 3, 2026, 4:27 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Genetics of Inherited Eye Disease

NCT02471287
View directory record Official record
Conditions
Genetic Eye Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
1 Year to 120 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 4:27 PM EST
Completed No phase listed Observational

Objective Brain Function Assessment of mTBI/Concussion in High School Athletes

NCT02661633
View directory record Official record
Conditions
Brain Injuries, Traumatic, Concussion, Brain, Concussion, Mild, Concussion, Intermediate, Concussion, Severe
Interventions
BrainScope Ahead 200iD, Advanced MRI Neuroimaging
Device
Lead sponsor
BrainScope Company, Inc.
Industry
Eligibility
13 Years to 19 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Fayetteville, Arkansas • Bethesda, Maryland • East Lansing, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Nov 3, 2026, 4:27 PM EST
Completed No phase listed Observational

Screening for Studies on Inherited Eye Diseases

NCT00001732
View directory record Official record
Conditions
Hereditary Eye Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 3, 2026, 4:27 PM EST
Active, not recruiting Phase 3 Interventional Results available

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
tafasitamab, rituximab, lenalidomide, placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
38
States / cities
Concord, California • Greenbrae, California • Pasadena, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 4:27 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Oral Alpha-Cyclodextrin for Decreasing Serum Cholesterol

NCT01131299
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Placebo, Alpha cyclodextrin
Other · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 75 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2016 · Synced Nov 3, 2026, 4:27 PM EST
Terminated Phase 1 Interventional

A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies

NCT02223598
View directory record Official record
Conditions
Lymphoid Hematological Malignancies, Relapsed and Refractory Multiple Myeloma
Interventions
CB-5083, Dexamethasone
Drug
Lead sponsor
Cleave Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Duarte, California • San Francisco, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Nov 3, 2026, 4:27 PM EST
Recruiting Phase 1Phase 2 Interventional

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

NCT07667400
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Hypopharyngeal Cancer, Carcinoma of Larynx, Oral Squamous Cell Carcinoma, Salivary Gland Cancer, Adenoid Cystic Carcinoma, Prostate Cancer, Metastatic Castration Resistant Prostate Cancer
Interventions
SX-682, DTX
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 4:27 PM EST
Terminated Phase 2 Interventional Results available

BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment

NCT02326844
View directory record Official record
Conditions
Ovarian Cancer
Interventions
BMN 673 (talazoparib)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Nov 3, 2026, 4:27 PM EST
Completed Phase 2 Interventional Results available

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib

NCT00609804
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Sorafenib, Erlotinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
16
States / cities
Fort Myers, Florida • Gainesville, Georgia • Marietta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Nov 3, 2026, 4:27 PM EST
Not yet recruiting Phase 2 Interventional

(Z)-Endoxifen in Girls With MAS-Associated Peripheral Precocious Puberty

NCT07869732
View directory record Official record
Conditions
Precocious Puberty, Gonadotropin-dependent
Interventions
(Z)-endoxifen
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
4 Years to 9 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 3, 2026, 4:27 PM EST
Not listed Phase 3 Interventional

The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis

NCT00012506
View directory record Official record
Conditions
Uveitis, Arthritis, Juvenile Rheumatoid
Interventions
TNFR:Fc
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 4:27 PM EST
Completed Phase 2 Interventional

HIV Maintenance Therapy With T-20 During HAART Interruption

NCT00013884
View directory record Official record
Conditions
HIV Infection
Interventions
T-20
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 4:27 PM EST
Completed Phase 4 Interventional

Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors

NCT00075166
View directory record Official record
Conditions
Brain Neoplasms, Neoplasm Metastasis
Interventions
Stereotactic surgery (SRS), Craniotomy
Procedure
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 4:27 PM EST
Active, not recruiting Not applicable Interventional

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

NCT05896189
View directory record Official record
Conditions
Breast Cancer, Cognitive Impairments
Interventions
Arm 1: Computerized Cognitive Training-Global Stimulation Games, Arm 2: Computerized Cognitive Training-Neuroplasticity Games
Behavioral
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 100 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
673
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 483 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Nov 3, 2026, 4:27 PM EST
Completed Phase 3 Interventional

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

NCT00694382
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Semuloparin sodium, Placebo (for semuloparin)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
3,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
48
States / cities
Birmingham, Alabama • Casa Grande, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Nov 3, 2026, 4:27 PM EST
Completed Phase 2 Interventional Results available

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

NCT00043979
View directory record Official record
Conditions
Sarcoma
Interventions
F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, melphalan, prednisone, sirolimus, tacrolimus, vincristine sulfate, peripheral blood stem cell transplantation, Filgrastim, Peripheral Blood Stem Cell donation
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Nov 3, 2026, 4:27 PM EST
Completed Phase 2 Interventional Results available

Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors

NCT00353977
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
ALVAC-CMV (vCP260)
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Nov 3, 2026, 4:27 PM EST
Recruiting Phase 1 Interventional

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

NCT06904066
View directory record Official record
Conditions
Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute
Interventions
aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500
Drug · Biological · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2026 · Synced Nov 3, 2026, 4:27 PM EST
Completed Phase 2 Interventional Results available

The Role of Hormones in Postpartum Mood Disorders

NCT00001481
View directory record Official record
Conditions
Postpartum Depression
Interventions
Estradiol, Placebo, Progesterone, leuprolide acetate
Drug · Other
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Nov 3, 2026, 4:27 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Fat Tissue Microperfusion to Measure Leptin Secretion and Its Relations With Fat Breakdown in Humans

NCT00001722
View directory record Official record
Conditions
Healthy, Obesity
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 3, 2026, 4:27 PM EST
Active, not recruiting Phase 2 Interventional Results available

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

NCT04458922
View directory record Official record
Conditions
Central Chondrosarcoma, Grade 2, Central Chondrosarcoma, Grade 3, Dedifferentiated Chondrosarcoma, Metastatic Clear Cell Sarcoma of Soft Tissue, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
Interventions
Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
14
States / cities
Los Angeles, California • Gainesville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 3, 2026, 4:27 PM EST